Glucagon - Global Strategic Business Report

The global market for Glucagon was estimated at US$434.2 Million in 2024 and is projected to reach US$547.2 Million by 2030, growing at a CAGR of 3.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Glucagon market.

Global Glucagon Market - Key Trends & Drivers Summarized

Why Is Glucagon a Critical Hormone in Metabolic and Emergency Medicine?

Glucagon, a peptide hormone produced by the pancreas, plays a vital role in glucose metabolism by stimulating the liver to release stored glucose, thereby increasing blood sugar levels. Traditionally known for its role in managing severe hypoglycemia in diabetic patients, glucagon has expanded its clinical applications beyond diabetes treatment. It is now being used in diagnostic imaging, gastrointestinal procedures, and even as a potential therapy for obesity and metabolic disorders. The growing prevalence of diabetes and the need for fast-acting, reliable treatments for hypoglycemic episodes have significantly boosted demand for glucagon-based therapies.

Recent advancements in glucagon formulations, including auto-injectors, nasal sprays, and long-acting analogs, have improved patient accessibility and ease of administration. These innovations have enhanced emergency hypoglycemia management, particularly for individuals who struggle with injectable treatments. Additionally, pharmaceutical companies are exploring novel applications for glucagon in metabolic disease modulation, including appetite regulation and energy balance, further expanding its therapeutic potential. As research continues to uncover new uses for glucagon, its role in modern medicine is becoming increasingly indispensable.

Which Medical Applications Are Driving Demand for Glucagon?

The primary use of glucagon remains in emergency medicine for the treatment of severe hypoglycemia in patients with type 1 and type 2 diabetes. Traditional glucagon injections and newer intranasal formulations are widely used by caregivers and healthcare providers to rapidly restore blood glucose levels in unconscious or severely hypoglycemic patients. However, recent advancements have expanded glucagon's use into new therapeutic areas, including diagnostic imaging and gastrointestinal (GI) procedures.

In diagnostic imaging, glucagon is used as a smooth muscle relaxant to improve the visualization of the gastrointestinal tract during radiological procedures such as MRI and CT scans. Its ability to temporarily reduce peristalsis makes it valuable for obtaining high-quality images of the stomach and intestines. Additionally, ongoing research is investigating glucagon's potential in obesity management, as it has been shown to suppress appetite and increase energy expenditure. With expanding applications in metabolic disease treatment and medical imaging, the demand for glucagon continues to rise across multiple healthcare sectors.

What Are the Latest Technological Innovations in Glucagon Drug Development?

Recent innovations in glucagon drug development have focused on improving formulation stability, ease of administration, and therapeutic efficacy. One of the most significant advancements is the introduction of ready-to-use auto-injectors and nasal spray formulations, which eliminate the need for reconstitution and improve emergency response times. These user-friendly delivery systems have increased glucagon adoption, particularly in home settings where rapid intervention is necessary.

Additionally, pharmaceutical companies are developing long-acting glucagon analogs designed for continuous glucose modulation in metabolic disorders. AI-driven drug discovery and peptide engineering techniques have enabled the optimization of glucagon analogs with improved pharmacokinetics, making them more suitable for long-term treatment applications. Furthermore, research into dual and triple hormone therapies combining glucagon with GLP-1 receptor agonists is gaining traction for treating obesity and type 2 diabetes. These advancements are positioning glucagon as a multi-functional hormone with significant therapeutic potential beyond emergency hypoglycemia management.

What Factors Are Fueling the Growth of the Glucagon Market?

The growth in the glucagon market is driven by several factors, including the rising incidence of diabetes, increasing awareness of hypoglycemia management, and expanding therapeutic applications. The growing diabetic population worldwide has heightened the demand for emergency glucagon treatments, particularly in home-use settings where caregivers require user-friendly solutions. The introduction of nasal and auto-injector formulations has further boosted adoption rates by improving ease of use.

Additionally, the expansion of glucagon's role in diagnostic imaging and metabolic disease treatment has created new market opportunities. Regulatory approvals for novel formulations and combination therapies are further accelerating industry growth. Pharmaceutical companies investing in peptide engineering and next-generation glucagon analogs are driving innovation, positioning glucagon as a key player in future metabolic therapies. As demand for effective, versatile hormone-based treatments continues to rise, the glucagon market is expected to experience strong and sustained growth.

Scope of Study:

The report analyzes the Glucagon market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Product (Injectable Glucagon, Inhalation Glucagon); Application (Hypoglycemia Application, Diagnostic Aid Application, Gastrointestinal Disorders Application, Cardiogenic Shock Application, Other Applications); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Injectable Glucagon segment, which is expected to reach US$353.9 Million by 2030 with a CAGR of a 3.3%. The Inhalation Glucagon segment is also set to grow at 5.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $118.3 Million in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $110.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Glucagon Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Glucagon Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Glucagon Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Amphastar Pharmaceuticals, Inc., Arecor Therapeutics plc, Aurobindo Pharma Limited, Avalon Pharma Private Limited, Bachem AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Glucagon market report include:

• Amphastar Pharmaceuticals, Inc.
• Arecor Therapeutics plc
• Aurobindo Pharma Limited
• Avalon Pharma Private Limited
• Bachem AG
• Bachem Holding AG
• Eli Lilly and Company
• Fresenius SE & Co. KGaA
• Fujifilm Holdings Corporation
• Hybio Pharmaceutical
• ILS Inc.
• Jin Dun Medical
• Novo Nordisk A/S
• Pfizer Inc.
• Piramal Pharma Solutions
• Svar Life Science
• Taj Pharmaceuticals Limited
• United Biotech (P) Limited
• Xeris Biopharma Holdings, Inc.
• Zealand Pharma A/S

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.